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ABSTRACT
Recent research on the relationship between osteo-
porosis and lactase persistence has revealed that these 
two factors are positively correlated. There is existing 
evidence that shows the domestication of cattle was 
a selective force for the lactase persistence allele. We 
hypothesize that this genetic change caused a shift 
in the ancestral physiological mechanism for calcium 
homeostasis, resulting in a derived calcium homeo-
stasis. Consequently, individuals with this derived 
calcium homeostasis are more susceptible to degen-
erative bone diseases, such as osteoporosis. Osteopo-
rosis is a topic of major health concern in the Unit-
ed States, considering that it is responsible for more 
hospital stays for women aged 45 or older than any 
other disease in America. Geriatric populations are 
the demographic most heavily affected by osteopo-
rosis—particularly postmenopausal women. Research 
has also indicated that roughly 20 percent of elderly 
patients die within the first year of a hip fracture and 
less than 50 percent return to their previous lifestyle. 
The health concerns associated with osteoporosis 
Ryan J. Glendenning and Aaron J. Williams
Implications for Treatment of 
Degenerative Bone Diseases in 
the 21st Century
CO-EVOLUTION OF CALCIUM 
HOMEOSTASIS AND 
LACTASE PERSISTENCE:
along with the expensive costs of treatment place a 
priority on alternative ways to treat and prevent this 
disease. We review the development of lactase per-
sistence along with important biological molecules 
involved in calcium homeostasis. We also discuss the 
physiology behind the ancestral calcium homeostasis 
and the derived calcium homeostasis, as well as po-
tential paths for further research.
INTRODUCTION
Osteoporosis is a degenerative bone disease recogniz-
able by a loss of bone mass density (BMD). Dual-en-
ergy X-ray absorptiometry (DXA) is a diagnostic 
technique used to evaluate the BMD of a patient.1 
While a DXA scan can assess BMD of the whole 
skeleton, it is usually focused on the hips and spine of 
a patient when searching for osteoporosis.1 The results 
of a DXA scan are then measured against a reference 
ALLELE:
an alternative form of a gene
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anism for calcium homeostasis, resulting 
in susceptibility to developing degenera-
tive bone diseases like osteoporosis.
DEVELOPMENT OF LACTASE 
PERSISTENCE
For ninety-nine percent of human history, 
humans would become lactose intolerant 
around early adulthood.15–17 Milk was 
primarily consumed during infancy and 
over time there became no need to digest 
milk.15 Around 10,000 years ago, muta-
tions developed in the genes regulating 
lactase, the enzyme that breaks down the 
lactose sugar.10, 11 Without the ancestral 
need to digest the milk into adulthood the 
lactase non-persistent (LNP) trait natu-
rally downregulates lactase production.16 
The lactose sugar is a disaccharide, which 
provides no caloric benefit because it can 
not be absorbed through the lumen of the 
Osteoporosis accounts 
for more hospital stays 
than any other disease in 
America, and treatments 
cost Americans over $22 
billion per year.
LACTASE PERSISTENCE
the activity of lactase (an enzyme that 
breaks down the sugar lactose) is con-
tinued into adulthood
population of young, healthy individuals. This comparison against 
the reference population is widely referred to as a T-score. The 
T-score measures how many standard deviations away from the 
reference population the patient’s BMD is. A diagnosis of os-
teoporosis occurs when a patient’s T-score is -2.5 or lower, i.e. 
2.5 standard deviations below the reference population.2 Elderly 
women are the most likely demographic group to develop the 
disease, although it can develop in anyone at any point in life.3, 4 
Osteoporosis accounts for more hospital stays for women aged 45 
or older than any other disease in America and treatments cost 
Americans over $22 billion per year.5, 6 For this reason, a drug 
that can effectively treat or even prevent this disease is a priority 
in the pharmaceutical community. Historically, osteoporosis was 
thought to be rather simple. However, new research has increased 
our understanding of the complex immunological and physiolog-
ical systems behind the disease.7, 8
Recently, a team of researchers led by Dr. Constance Hilliard 
from the University of North Texas ran a comparative study be-
tween West and East Africans. West Africans have some of the 
lowest rates of osteoporosis in the world, with around 3 hip frac-
tures per 100,000 postmenopausal women, while East Africans 
have high rates of osteoporosis, with around 243 hip fractures per 
100,000 postmenopausal women.9 The fracture rates were posi-
tively correlated (r = 0.841) with milk consumption and positive-
ly correlated with lactase persistence (r = 0.735).9 East Africans 
adopted cattle domestication between 2,700–6,800 years ago, and 
have been consuming milk from cattle ever since.10 Milk contains 
lactose, a sugar only digestible by people who produce the lactase 
enzyme. The domestication of cattle created a selective pressure 
for people who have the lactase persistence (LP) allele.11–13
Current guidelines on osteoporosis encourage maximum cal-
cium consumption.14 However, Dr. Hilliard’s study contradicts 
this suggestion. According to Dr. Hilliard, the incidence of osteo-
porosis increases with calcium and milk consumption. The impli-
cations of these findings are critical to understanding the etiolog-
ical processes of osteoporosis. Identifying risk factors in patients 
earlier, and more accurately, could prevent injuries and hospital 
stays. Based on Dr. Hilliard’s conclusions, we hypothesize the do-
mestication of cattle was a selective force for the LP allele. This 
genetic change caused a shift in the ancestral physiological mech-
LUMEN:
the inner space of a tube-shaped 
structure
HOMEOSTASIS
the regulation of a system within an  
organism to remain at a nearly  
constant level
DISACCHARIDE
a molecule comprised of two individual 
sugar molecules
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small intestine in its natural form. However, lactase cleaves lac-
tose into glucose and galactose, two monosaccharides capable of 
providing calories. Mutations in the lactase (LCT) gene, located 
on chromosome 2, allowed humans to successfully digest milk 
through adulthood.10, 11, 15 
Upon the domestication of cattle, milk became an easy 
source of calories for those who could digest the lactose sugar.18 
Consuming lactose in the absence of lactase can create painful 
abdominal cramps and gas, discouraging those who are lactose 
intolerant from consuming milk.18 Those who had the LP mu-
tations in milk-consuming populations possessed a selective ad-
vantage over those who did not, since only LP individuals could 
benefit from the high nutritional content of milk.19 This selective 
advantage allowed those who expressed the LP trait to pass on 
their genes.20 This selecting force, along with other cultural and 
environmental factors, allowed LP to replace lactose intolerance 
in certain parts of the world.10, 18 In populations with European 
ancestry, the T-13910 allele on the LCT gene is responsible for 
the expression of lactase. The T-13910 variant is only present at 
significant levels in populations with European ancestry.10, 11 In 
Africa, several other variants of the LCT gene have been identi-
fied as causes of LP trait expression.10 
Individuals selected for the LP trait shifted away from the 
ancestral state of LNP. This shift resulted in LP individuals con-
suming high levels of milk and thus a high intake of dietary cal-
cium. It was this continuous high intake of dietary calcium, made 
possible by a naturally selected genetic change, that led to a phys-
iological change in the calcium homeostasis for LP individuals. 
That change will be referred to as the derived calcium homeosta-
sis. LNP individuals did not have access to excess calcium from 
milk and retained their ancestral calcium homeostasis. 
IMPORTANT BIOLOGICAL MOLECULES
INVOLVED IN CALCIUM HOMEOSTASIS
Calcium is an element found in plants and animals. It is classi-
fied as a micronutrient and a mineral, meaning it is needed in 
small amounts to sustain life. In humans, calcium serves three 
important functions of normal physiology: muscle contraction, 
cellular signaling, and blood clotting.21 Humans have more hor-
mones that raise blood calcium levels as opposed to hormones 
that lower blood calcium levels, indicating that adequate calcium 
is necessary for maintaining many cellular 
processes.21 One such hormone is parathy-
roid hormone (PTH).
PTH is synthesized in the parathyroid 
glands located posterior to the thyroid 
gland in the lower neck.22 This hormone 
has direct effects on bones and kidneys. It 
binds to cell surface receptors on certain 
bone cells to increase the ratio of bone 
resorption to bone building.22 PTH also 
binds to cell surface receptors on the kid-
ney tubules to cause reabsorption of calci-
um into the plasma.22 Reabsorption of cal-
cium from the kidneys helps to minimize 
the loss of calcium through excretion. The 
last function of PTH is indirect. PTH 
causes cellular modifications of Vitamin 
D3 in the kidney to turn Vitamin D3 into 
its biologically active form, 1α,25-dihy-
droxyvitamin D3, also known as calcitriol. 
PTH accomplishes this by increasing pro-
duction of the enzyme 1-α-hydroxylase, 
which converts 25-hydroxyvitamin D3 
into calcitriol. Calcitriol increases plasma 
calcium by absorbing it from the small in-
testinal lumen. It also acts to cause bone 
resorption by increasing osteoclast pro-
duction.23 In a correctively functioning 
calcium homeostasis, average bone build-
ing rate roughly equals average bone re-
sorption rate. This maintains BMD.
Bones release and sequester calcium 
based on their anatomical composition. 
The hard part of bone is made of a cal-
cium phosphate crystal known as calcium 
hydroxyapatite.24 These crystals are built 
by bone building cells, osteoblasts, and are 
broken down by bone dissolving cells, os-
teoclasts. Osteoblasts form these hydroxy-
apatite crystals by combining water with 
secreted calcium and phosphates.24 The 
3
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bone matrix is maintained by osteoblasts 
trapped within the bone matrix known as 
osteocytes. When these crystals are bro-
ken down by osteoclasts, calcium leaves 
the bone and enters the bloodstream.25 
Once in the bloodstream, the body utilizes 
this calcium for life sustaining functions.21 
Bones serve as storage banks for calcium 
in this homeostatic mechanism. Proper 
regulation of osteoblasts and osteoclasts 
is necessary for bones to effectively serve 
this purpose.
Receptor activator of nuclear factor 
kappa-B ligand (RANK-L), receptor 
activator of NF-κB (RANK), and osteo-
protegerin (OPG) are key signaling-pro-
teins involved in osteoblast and osteo-
clast regulation.26 When calcitriol binds 
to osteoblasts, RANK-L is released into 
the extracellular environment. RANK-L 
then binds RANK on osteoclast precur-
sors, causing production of osteoclasts by 
a process called osteoclastogenesis.26 OPG 
is a signaling-protein that functions as a 
RANK receptor. It binds to RANK-L with a high affinity and 
prevents RANK-L from binding to RANK, therefore inhibiting 
osteoclastogenesis and conserving BMD.26 OPG is vitally im-
portant in maintaining a healthy BMD.
THE EVOLUTION OF THE DERIVED CALCIUM 
HOMEOSTASIS
Preagricultural diets had extremely low dietary calcium levels, 
which can be partially attributed to the absence of milk.27–29 
Therefore, this ancestral calcium homeostasis would have been 
extremely advantageous for our early ancestors before dairy ag-
riculture was present. We theorize that the ancestral calcium ho-
meostasis is defined as having chronically high PTH and OPG 
levels that are necessary to efficiently utilize the low levels of di-
etary calcium.
High PTH levels in the presence of low dietary calcium is 
beneficial for the ancestral calcium homeostasis because PTH 
allows for maximum absorption of calcium through the small 
intestine via calcitriol and the maximum reabsorption of calci-
um from the renal tubules.22 The calcium conserving purposes of 
PTH in the ancestral calcium homeostasis allows individuals to 
maintain a healthy BMD. The high presence of OPG mediates 
the negative bone resorption associated with PTH and conserves 
BMD by inhibiting osteoclastogenesis.22 This ancestral calcium 
homeostasis allowed our ancestors to maintain bone health de-
spite having a low dietary calcium intake. Research shows that 
having high levels of OPG and PTH present at the same time 
significantly increases bone mineral density.22, 30, 31 Further stud-
ies have shown that the body can adapt its calcium homeostasis 
physiology in the presence of low calcium levels without compro-
mising bone health in the process.32
The introduction of dairy agriculture along with the selection 
for LP genotypes allowed individuals to consume high amounts 
of dietary calcium in the form of milk.18 This large influx of di-
etary calcium led to high levels of calcium in the bloodstream, 
which would decrease the relative amount of PTH.22, 33, 34 With 
PTH levels decreased, osteoblastic OPG production would also 
decrease in an effort to conserve energy. This would create a new 
calcium homeostasis setpoint for LP individuals where both PTH 
and OPG levels are low. Although this high calcium intake leads 
These guidelines are 
insufficient for prevention 
and treatment of 
osteoporosis under our 
model of the derived 
calcium homeostasis.
LIGAND:
a molecule that binds to another molecule
CALCITRIOL:
the biologically active form of 
vitamin D
a receptor that can recognize and bind 
cell-signaling proteins as an inhibitor to 
prevent normal binding
DECOY RECEPTOR:
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to energy conservation, the derived calcium homeostasis is also 
susceptible to dysfunction. In times of stress, such as low calcitri-
ol production or low calcium consumption, PTH levels rise and 
cause bone resorption.35 Without the protective effects of OPG, 
osteoclast activity is minimally inhibited and outpaces osteoblast 
activity.26 More simply stated, the breakdown of bone via PTH 
would go unchecked and bone health would suffer. Due to the 
decrease in estrogen production levels associated with the post-
FIGURE 1
Figure 1. The diagram above shows the divergence of the derived calcium homeostasis from the ancestral 
calcium homeostasis along with the basic functions of each homeostatic mechanism. Parathyroid hormone 
(PTH) binds to surface receptors on osteoclasts to increase bone resorption activity. PTH also causes 
resorption of calcium into blood plasma by binding to receptors on kidney tubules. Osteoprotegerin (OPG) 
inhibits the bone degrading effects of PTH. In the derived calcium homeostasis, low PTH and OPG levels in-
crease the risk for osteoporosis development since PTH levels can rise with inadequate calcitriol or calcium. 
With PTH levels raised, bone resorption increases. In the ancestral calcium homeostasis, high OPG levels 
inhibit the bone resorption aspect of PTH and therefore decreases the risk for osteoporosis development.
menopausal stage of life, postmenopausal 
women with this calcium homeostasis are 
at a high risk for developing osteoporosis. 
Estrogen has been seen to provide a pro-
tective effect against osteoporosis since it 
positively regulates OPG expression.26
5
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IMPLICATIONS FOR THE TREATMENT OF 
OSTEOPOROSIS
Current guidelines for osteoporosis prevention from the National 
Osteoporosis Foundation (NOF) suggest “get enough calcium, 
eat a well-balanced diet, engage in regular exercise, eat foods that 
are good for bone health such as fruits and vegetables, and avoid 
smoking and limit alcohol to 2–3 drinks per day.”14 These guide-
lines are insufficient for prevention and treatment of osteoporo-
sis under our model of the derived calcium homeostasis. Studies 
have shown that dietary calcium and vitamin D supplements 
alone have mixed results in their effectiveness to reduce frac-
tures.36–38 Current treatments for osteoporosis do not take into 
account this difference between an ancestral and a derived cal-
cium homeostasis. These treatments include supplementing with 
calcium, vitamin D, estrogen, calcitonin, and/or bisphosphonate 
derivatives. While bisphosphonate derivatives have been shown 
to effectively treat osteoporosis, there have been major concerns 
regarding long-term safety of their use.39, 40
The drug known as denosumab targets the RANK-L-RANK-
OPG pathway, a key aspect of the derived calcium homeostasis, 
and provides ample evidence to support an effective treatment 
of osteoporosis.39 The derived calcium homeostatic mechanism 
needs to be considered in order to develop more effective treat-
ments and preventions for osteoporosis. Sampling serum bio-
markers from a large population of diverse individuals would 
allow for further evidence to support our hypothesis. Specifically, 
research might include looking at the serum levels of PTH and 
OPG in lactase persistent and lactase non-persistent individuals.
Genetic screening for the presence of the LP allele, as well 
as sampling PTH and OPG serum levels, could be an import-
ant step in the prevention and treatment of osteoporosis. This 
method would identify risk factors for young patients and could 
lead to the early implementation of preventative treatment for 
osteoporosis. Currently, US health insurance companies will not 
cover the use denosumab derivatives for patients.41, 42 In order for 
insurance companies to cover this preventative treatment, studies 
need to be conducted to determine if this type of preventative 
treatment would save them money.
Recent research suggests that mortali-
ty rates for hip fractures in North America 
alone are between 14 percent–36 percent 
within 1 year of surgery and less than 50 
percent of patients return to their previ-
ous lifestyle.43, 44 Hip fracture surgery has 
also been shown to be associated with an 
increase in dependency on long-term in-
stitutional care, an increased incidence of 
entering a low-income status, an increased 
risk of coronary heart disease and other 
postoperative complications like periop-
erative anemia, gastrointestinal anemia, 
cognitive alterations, and embolisms.45–47 
These potential health and lifestyle con-
sequences combined with the immense 
cost of treating osteoporosis indicate the 
dire need for future osteoporosis-related 
research.
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